1 Green Flag and 1 Red Flag for Bluebird Bio Stock
No stock is entirely risk-free, especially stocks like Bluebird Bio (NASDAQ: BLUE). The small-cap company's shares have plunged by 84% in the past three years.
The gene editing specialist has had clinical, regulatory, and financial issues that account for its lagging the market. However, some might think that at current levels, Bluebird Bio is practically a steal.
Is that the case? Let's consider one reason to buy the stock and one to avoid it.
Source Fool.com
